anti-Vg9d2 TCR/anti-CD33 gamma-delta T-cell engager (Shattuck Labs/University of Wisconsin School of Medicine and Public Health)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug Nameanti-Vg9d2 TCR/anti-CD33 gamma-delta T-cell engager (Shattuck Labs/University of Wisconsin School of Medicine and Public Health)
Drug Alias NameCD33-GADLEN
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsT lymphocytes stimulantsT-cell receptor modulators +[4] 
TargetsMyeloid cell surface antigen CD33T-cell receptor
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Wisconsin School Of Medicine And Public Health (Uwsmph)
China Registration ClassN/A

Develop Information

Active CompaniesShattuck Labs IncUniversity Of Wisconsin School Of Medicine And Public Health (Uwsmph)
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A